START-UP’s 2012 Medical Device Census
This article was originally published in Start Up
Our data-driven review of the portfolios of more than two dozen leading medical device VCs show that the median life span of venture-backed companies hovers at seven years. Younger medtech companies are getting by – and getting farther in the regulatory process – with less capital, reflecting the current state of an industry that sees a whole lot of belt tightening in its future.
You may also be interested in...
Neuronetics Brightens Outlook For Neuro Devices
Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.
Can Simpirica Simplify Spine Stabilization?
Founded at the height of the spine industry’s surge, Simpirica Spine Inc. has developed a dynamic stabilization device that is reminiscent in its simplicity and novelty of past interspinous spacers. The company will soon embark on a 400-patient pivotal trial in the US testing its LimiFlex against posterolateral fusion in treating degenerative spondylolisthesis. A successful outcome in the trial could help offset some of the setbacks the spine industry has suffered over the past five years.
Attack Of The Hair Restoration Robot
Robots invaded the operating room years ago, providing surgeons with high precision tools to perform a wide range of procedures from prostatectomies to partial knee replacements. Now, Restoration Robotics is hoping to take over the private practices of hair restoration surgeons. Last year, the venture-backed company launched ARTAS, a robotic system capable of minimally invasive removal of hair follicles used in hair transplants. Restoration Robotics executives see ARTAS as a way to level the playing field between hair restoration surgeons who are capable of performing the sometimes tricky follicular unit extraction and those who want to offer the procedure but don’t have the skills or resources. By conservative estimates, FUE accounts for less than 20% of the $1 billion hair restoration industry. Restoration Robotics sees its robotic system enabling more surgeons to perform FUEs, which could convince more prospective patients to undergo a hair restoration procedure.